Coexistence of Hodgkin and Non-Hodgkin Lymphoma; Composite Lymphoma [CL] in a Patient Presenting with Waxing and Waning Lymphadenopathy

Geladari, Eleni; Dimopoulou, Georgia; Margellou, Evangelia; Paraskevas, Andreas; Kafetzis, Georgios; Rontogianni, Dimitra; Vadiaka, Maria

doi:10.2174/1871529x19666191014111118

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 79 cHL/diffuse large B-cell composite lymphomas from 35 articles were analyzed [ 1 , 3 , 6 , 13 , 14 , 16 , 58 , 64 , 66 , 76 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 ].…”

Section: Resultsmentioning

confidence: 99%

Plasticity in Classical Hodgkin Composite Lymphomas: A Systematic Review

Trécourt

Donzel

Fontaine

et al. 2022

Cancers

View full text Add to dashboard Cite

The co-occurrence of several lymphomas in a patient defines composite/synchronous lymphoma. A common cellular origin has been reported for both contingents of such entities. In the present review, we aimed to gather the available data on composite lymphomas associating a classical Hodgkin lymphoma (cHL) with another lymphoma, to better understand the plasticity of mature B and T-cells. This review highlights that >70% of patients with a composite lymphoma are ≥55 years old, with a male predominance. The most reported associations are cHL with follicular lymphoma or diffuse large B-cell lymphoma, with over 130 cases reported. The cHL contingent is often of mixed cellularity type, with a more frequent focal/weak CD20 expression (30% to 55.6%) compared to de novo cHL, suggesting a particular pathophysiology. Moreover, Hodgkin cells may express specific markers of the associated lymphoma (e.g., BCL2/BCL6 for follicular lymphoma and Cyclin D1 for mantle cell lymphoma), sometimes combined with common BCL2/BCL6 or CCND1 rearrangements, respectively. In addition, both contingents may share similar IgH/IgK rearrangements and identical pathogenic variants, reinforcing the hypothesis of a common clonal origin. Finally, cHL appears to be endowed with a greater plasticity than previously thought, supporting a common clonal origin and a transdifferentiation process during lymphomagenesis of composite lymphomas.

show abstract

Section: Resultsmentioning

confidence: 99%

Plasticity in Classical Hodgkin Composite Lymphomas: A Systematic Review

Trécourt

Donzel

Fontaine

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…When HL or NHL appears before the other, it is called metachronous lymphoma (ML), two histological forms of HL or NHL appearing together is referred to as synchronous lymphoma. However, CL refers to both histological types of synchronous lymphoma that occur in the same anatomical site[ 2 ]. In this article, we report a patient with ML, whose biopsy of a right cervical lymph node initially confirmed classical HL (CHL), with typical reed–sternberg (RS) cells expressing CD30 and PAX-5.…”

Section: Introductionmentioning

confidence: 99%

Metachronous mixed cellularity classical Hodgkin’s lymphoma and T-cell leukemia/lymphoma: A case report

Dong¹,

Deng²,

Li³

2021

WJCC

View full text Add to dashboard Cite

BACKGROUND The development of peripheral T-cell lymphoma (PTCL) after chemotherapy for Hodgkin’s lymphoma (HL) is rare, and highly aggressive TCL/leukemia has not been reported to date. The relationship between HL and PTCL needs further exploration to understand the pathogenesis of metachronous lymphoma (ML) and find effective treatment options. We report a patient with ML, whose biopsy of a right cervical lymph node initially confirmed classical HL (CHL). CASE SUMMARY We report a patient with ML, whose biopsy of a right cervical lymph node initially confirmed CHL, with typical reed–sternberg cells expressing CD30 and PAX-5. T-cell leukemia/lymphoma occurred 3 years after treatment, and a lymph node biopsy at the onset confirmed PTCL, nonspecific type, expressing CD3, CD4 and CD8. The patient was treated with standard doses of chemotherapy, programmed cell death-ligand 1 monoclonal antibody, and chidamide, all of which failed to achieve complete remission. The patient was diagnosed with refractory state, and eventually died of leukocyte stasis. CONCLUSION The accuracy of the diagnosis needs to be confirmed when chemotherapeutic drugs are not effective.

show abstract